Skip to main content

Diabetes & Weight Loss News

The 30th Annual Obesity Society Meeting brings exciting insights on drugs and mobile health.
Retrofit CEO Jeff Hyman explains what makes data-driven weight loss – using Skype sessions and Wifi scales– so different.
During the US Open tennis tournament earlier this month, Larry Soler of the Partnership for a Healthier America (PHA) announced a pair of new initiatives to promote...
Exercise and weight loss have been shown to significantly reduce a person’s risk of moving from prediabetes to type 2 diabetes. However, insurance coverage for these...
On September 17, Vivus announced that its obesity medication Qsymia (formerly Qnexa) is now available on the US market – this happened at least several weeks earlier...
Dr. Arya Sharma highlights the most important weight loss tip everyone should know and why weight maintenance is a major achievement.
On July 17, the FDA approved Vivus’ weight-loss medication Qsymia (formerly called Qnexa), just several weeks after the approval of Arena’s Belviq (see new now next in...
Kelly reflects on a major advance in obesity treatment and highlights a memorable day for diabetes at the Major League Baseball Hall of Fame.
On June 27, the FDA approved Arena Pharmaceutical’s weight-loss drug Belviq (lorcaserin), the first weight-loss drug to be approved in the US in 13 years. Belviq is...
The Obesity Society's annual meeting has long been our favorite place to catch up on the basic science research behind this critical problem.
On May 14, HBO premiered its four-part documentary series on obesity, The Weight of the Nation . Each part – entitled “Consequences,” “Choices,” “Children in Crisis,”...
Several months after an FDA advisory committee delivered an overwhelmingly positive vote (20-2) in favor of approving Vivus’ Qnexa for the treatment of obesity, the...
(S)he said what?!?
We had the privilege of attending the inaugural Partnership for a Healthier America (PHA) Building a Healthier Future Summit in late 2011 in Washington, DC, where we...
diaTribe 's take on the recent New England Journal of Medicine's piece on weight gain - and loss!
As we have previously written, Vivus’ weight loss drug Qnexa is up for approval in the US in April of this year. Encouragingly, Vivus announced recently that, if...
In late November, the Centers for Medicare and Medicaid Services (the federal agency that administers the two public insurance programs) announced that Medicare would...
Recently, increasing evidence has suggested that weight-loss surgery (called “bariatric surgery”) can help improve type 2 diabetes management (or even cause its reversal...
Over the past several years, the use of GLP-1 drugs (such as Byetta and Victoza) together with basal insulins (such as Lantus and Levemir) as a treatment for type 2...
If you’ve been following our coverage of Orexigen’s obesity drug, Contrave, you’re likely aware that it has been through a regulatory rollercoaster over the past few...

Pages